small molecule

VALTOCO

DIAZEPAM

Loss of exclusivityJune 2042latest FDA-listed patent expiry

CompanyNeurelis Inc →See this company's full patent-cliff portfolio

Drug detail

Brand name	VALTOCO
Active ingredient	DIAZEPAM
Strength	10MG/SPRAY
Dosage form	SPRAY
Route	NASAL
Modality	Small molecule
FDA approval	January 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12599611	June 2042	use U-4455
12324852	October 2032	use U-4173
12337061	June 2032	use U-4173
12521400	March 2029	product
8895546	March 2029	product
11241414	March 2029	product
12268664	March 2029	product
11793786	March 2029	product

Regulatory exclusivity

Code	Expires
NPP	April 2028
ODE-279	January 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Neurelis Inc